A blood screening test for Alzheimer's disease

Sid E. O'Bryant; Melissa Edwards; Leigh Johnson; James Hall; Alcibiades E. Villarreal; Gabrielle B. Britton; Mary Quiceno; C. Munro Cullum; Neill R. Graff-Radford

doi:10.1016/j.dadm.2016.06.004

A blood screening test for Alzheimer's disease

Sid E. O'Bryant, Melissa Edwards, Leigh Johnson, James Hall, Alcibiades E. Villarreal, Gabrielle B. Britton, Mary Quiceno, C. Munro Cullum, Neill R. Graff-Radford

Research output: Contribution to journal › Article › peer-review

51 Scopus citations

Abstract

Introduction: This study combined data across four independent cohorts to examine the positive and negative predictive values of an Alzheimer's disease (AD) blood test if implemented in primary care. Methods: Blood samples from 1329 subjects from multiple independent, multiethnic, community-based, and clinic-based cohorts were analyzed. A "locked-down" referent group of 1128 samples was generated with 201 samples randomly selected for validation purposes. Random forest analyses were used to create the AD blood screen. Positive (PPV) and negative (NPV) predictive values were calculated. Results: In detecting AD, PPV was 0.81, and NPV was 0.95 while using the full AD blood test. When detecting mild cognitive impairment, PPV and NPV were 0.74 and 0.93, respectively. Preliminary analyses were conducted to detect any "neurodegenerative disease". The full 21-protein AD blood test yielded a PPV of 0.85 and NPV of 0.94. Discussion: The present study creates the first-ever multiethnic referent sample that spans community-based and clinic-based populations for implementation of an AD blood screen.

Original language	English
Pages (from-to)	83-90
Number of pages	8
Journal	Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring
Volume	3
DOIs	https://doi.org/10.1016/j.dadm.2016.06.004
State	Published - 2016

Keywords

Alzheimer's disease
Blood test
Diagnosis
Predictive power
Primary care
Screening

Access to Document

10.1016/j.dadm.2016.06.004

Cite this

@article{5319275fb92b43579b25e155fa3dd568,

title = "A blood screening test for Alzheimer's disease",

abstract = "Introduction: This study combined data across four independent cohorts to examine the positive and negative predictive values of an Alzheimer's disease (AD) blood test if implemented in primary care. Methods: Blood samples from 1329 subjects from multiple independent, multiethnic, community-based, and clinic-based cohorts were analyzed. A {"}locked-down{"} referent group of 1128 samples was generated with 201 samples randomly selected for validation purposes. Random forest analyses were used to create the AD blood screen. Positive (PPV) and negative (NPV) predictive values were calculated. Results: In detecting AD, PPV was 0.81, and NPV was 0.95 while using the full AD blood test. When detecting mild cognitive impairment, PPV and NPV were 0.74 and 0.93, respectively. Preliminary analyses were conducted to detect any {"}neurodegenerative disease{"}. The full 21-protein AD blood test yielded a PPV of 0.85 and NPV of 0.94. Discussion: The present study creates the first-ever multiethnic referent sample that spans community-based and clinic-based populations for implementation of an AD blood screen.",

keywords = "Alzheimer's disease, Blood test, Diagnosis, Predictive power, Primary care, Screening",

author = "O'Bryant, {Sid E.} and Melissa Edwards and Leigh Johnson and James Hall and Villarreal, {Alcibiades E.} and Britton, {Gabrielle B.} and Mary Quiceno and Cullum, {C. Munro} and Graff-Radford, {Neill R.}",

note = "Funding Information: Research reported in this publication was supported by the National Institute on Aging (NIA) under Award Numbers AG039389 and AG12300. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Publisher Copyright: {\textcopyright} 2016 The Authors.",

year = "2016",

doi = "10.1016/j.dadm.2016.06.004",

language = "English",

volume = "3",

pages = "83--90",

journal = "Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring",

issn = "2352-8729",

publisher = "Elsevier BV",

}

TY - JOUR

T1 - A blood screening test for Alzheimer's disease

AU - O'Bryant, Sid E.

AU - Edwards, Melissa

AU - Johnson, Leigh

AU - Hall, James

AU - Villarreal, Alcibiades E.

AU - Britton, Gabrielle B.

AU - Quiceno, Mary

AU - Cullum, C. Munro

AU - Graff-Radford, Neill R.

N1 - Funding Information: Research reported in this publication was supported by the National Institute on Aging (NIA) under Award Numbers AG039389 and AG12300. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Publisher Copyright: © 2016 The Authors.

PY - 2016

Y1 - 2016

N2 - Introduction: This study combined data across four independent cohorts to examine the positive and negative predictive values of an Alzheimer's disease (AD) blood test if implemented in primary care. Methods: Blood samples from 1329 subjects from multiple independent, multiethnic, community-based, and clinic-based cohorts were analyzed. A "locked-down" referent group of 1128 samples was generated with 201 samples randomly selected for validation purposes. Random forest analyses were used to create the AD blood screen. Positive (PPV) and negative (NPV) predictive values were calculated. Results: In detecting AD, PPV was 0.81, and NPV was 0.95 while using the full AD blood test. When detecting mild cognitive impairment, PPV and NPV were 0.74 and 0.93, respectively. Preliminary analyses were conducted to detect any "neurodegenerative disease". The full 21-protein AD blood test yielded a PPV of 0.85 and NPV of 0.94. Discussion: The present study creates the first-ever multiethnic referent sample that spans community-based and clinic-based populations for implementation of an AD blood screen.

AB - Introduction: This study combined data across four independent cohorts to examine the positive and negative predictive values of an Alzheimer's disease (AD) blood test if implemented in primary care. Methods: Blood samples from 1329 subjects from multiple independent, multiethnic, community-based, and clinic-based cohorts were analyzed. A "locked-down" referent group of 1128 samples was generated with 201 samples randomly selected for validation purposes. Random forest analyses were used to create the AD blood screen. Positive (PPV) and negative (NPV) predictive values were calculated. Results: In detecting AD, PPV was 0.81, and NPV was 0.95 while using the full AD blood test. When detecting mild cognitive impairment, PPV and NPV were 0.74 and 0.93, respectively. Preliminary analyses were conducted to detect any "neurodegenerative disease". The full 21-protein AD blood test yielded a PPV of 0.85 and NPV of 0.94. Discussion: The present study creates the first-ever multiethnic referent sample that spans community-based and clinic-based populations for implementation of an AD blood screen.

KW - Alzheimer's disease

KW - Blood test

KW - Diagnosis

KW - Predictive power

KW - Primary care

KW - Screening

UR - http://www.scopus.com/inward/record.url?scp=84977649614&partnerID=8YFLogxK

U2 - 10.1016/j.dadm.2016.06.004

DO - 10.1016/j.dadm.2016.06.004

M3 - Article

AN - SCOPUS:84977649614

SN - 2352-8729

VL - 3

SP - 83

EP - 90

JO - Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring

JF - Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring

ER -

A blood screening test for Alzheimer's disease

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this